🧾 What This Document Is

This is Zimmer Biomet’s DEF 14A proxy statement, filed ahead of its 2026 annual shareholder meeting. It explains what shareholders will vote on, provides details about the board and executive pay, and includes a shareholder proposal.
👉 Think of it as a “voter guide” for company decisions. You’ll find everything from director bios to CEO compensation here.

🏢 What The Company Does

Zimmer Biomet is a global medical device company focused on musculoskeletal health. They design, manufacture, and sell products like joint replacements, surgical tools, and digital/robotic tech used in orthopedic surgeries.
👉 In simple terms, they make devices that help people move better—like artificial knees and hips—sold in over 100 countries.

💰 Financial Highlights (From Summary Tables)

2025 Audit Fees: $10.7 million paid to PwC (up from $10.6M in 2024).
CEO Total Compensation: $14.0 million for Ivan Tornos in 2025 (salary + bonuses + stock awards).
Other Named Executives: Pay ranged from $5.6M to $7.5M.
👉 Executive pay is tied to performance metrics like revenue growth and profitability—common in large companies.

🚀 Key Moves & Governance Updates

Board Leadership: CEO Ivan Tornos is now also Chairman (combined roles). Michael J. Farrell is Lead Independent Director.
Shareholder Proposal: Someone wants the board to split the Chairman and CEO roles. The board recommends voting AGAINST—they say flexibility is better than a one-size-fits-all rule.
👉 This is a hot topic in corporate governance: whether having one person lead both management and the board reduces oversight.

📦 Board of Directors Nominees

Ten directors are up for election. Key highlights:

Ivan Tornos (CEO) – Age 50, with deep medical device experience.
Michael J. Farrell – CEO of ResMed, now Lead Independent Director.
Maria Teresa Hilado – Former CFO of Allergan, chairs the Audit Committee.
Sreelakshmi Kolli – Chief Product/Digital Officer at Align Technology.
👉 The board emphasizes diversity in skills: digital tech, global ops, finance, and healthcare expertise.

📜 Voting Matters & Board Recommendations

Shareholders will vote on:

Elect directors → Board says FOR all.
Ratify PwC as auditor → FOR.
Approve executive pay → FOR (advisory vote).
Consider shareholder proposal on independent chairman → AGAINST.
👉 The board believes its current structure—with a strong Lead Independent Director—works well.

🔮 What’s Next

Annual meeting will be held virtually—details in the notice.
The board continues focusing on digital/robotic innovation and global expansion.
Succession planning is active—30% of top leaders turned over in 2025.
👉 Zimmer Biomet is pushing into connected health and AI-driven tech, which could shape its future growth.

⚖️ Big Picture

Strengths (👍):

Diverse, experienced board with strong governance (majority vote standard, proxy access).
Clear pay-for-performance executive compensation.
Active shareholder engagement (reached out to holders of ~64% of shares).

Risks (⚠️):

Operating in a competitive, regulated medical device market.
Subject to pricing pressures and reimbursement changes.
Governance debate over board leadership structure could distract.

🧠 The Analogy

Think of Zimmer Biomet as a ship navigating a complex sea. The board is the crew—each member brings specific skills (navigation, engineering, medicine). The CEO is the captain who’s now also setting the course (Chairman). Some passengers (shareholders) want a separate captain and navigator for checks and balances, but the crew says they’ve got the experience and tools to steer safely.

📇 Key Contacts & People

Ivan Tornos: Chairman, President & CEO
Suketu Upadhyay: CFO (contact via corporate secretary)
Keri Matson: VP, Corporate Secretary
Zimmer Biomet HQ: 345 East Main Street, Warsaw, IN 46580
Investor Relations: Listed on company website for shareholder inquiries.

🧩 Final Takeaway

This proxy is about governance, pay, and board direction. Zimmer Biomet’s board is pushing for continuity—keeping the CEO as chairman and rejecting a split-role proposal—while shareholders get a chance to weigh in on pay and oversight. The company is leaning into digital health innovation amid a competitive landscape.

ZIMMER BIOMET HOLDINGS, INC. — DEF 14A Filing